Ticlopidine hydrochloride NEW
| Price | $30 |
| Package | 1mL |
| Supply Ability: | 10g |
| Update Time: | 2026-05-29 |
Product Details
| Product Name: Ticlopidine hydrochloride | CAS No.: 53885-35-1 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2026/05/29 |
Product Introduction
Bioactivity
| Name | Ticlopidine hydrochloride |
| Description | Ticlopidine hydrochloride (Ticlodix) is an effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. |
| In vitro | Oral administration of Ticlopidine HCl in rats enhances the affinity of cyclase on platelet membranes for prostaglandin E1, subsequently activating both the basal and prostaglandin E1-stimulated without affecting the enzyme activity induced by adenosine or sodium fluoride. Ticlopidine HCl exhibits an inhibitory effect on platelet aggregation with an IC50 of 2 μM in males. |
| In vivo | Ticlopidine HCl inhibits platelet aggregation by activating basal PGE1-induced cyclase activity, blocking the enhancement of cyclase activity induced by PGE2, thereby increasing platelet c-AMP levels, and suppressing prostaglandin synthesis from endogenous substrates. Additionally, it alters platelet membrane function and inhibits aggregation through the blockade of ADP receptors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 30 mg/mL (99.92 mM), Sonication is recommended. DMSO : 65 mg/mL (216.49 mM), Sonication is recommended. |
| Keywords | Ticlopidine Hydrochloride | Ticlopidine | P1 receptor | Inhibitor | inhibit | AdenosineReceptor | Adenosine Receptor |
| Inhibitors Related | Xanthine | Theophylline monohydrate | Diphylline | Adenosine monophosphate | Acefylline | Sulcatone | Adenosine 5'-monophosphate monohydrate | Inosine | Theobromine | Adenosine 5'-monophosphate disodium salt | Theophylline | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $6.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-02 | |
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-02 | ||
| $30.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-28 | |
| $30.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-28 | |
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $1.00 |
Wuhan Dujiang Industrial Co., Ltd.
|
2023-04-12 | ||
|
Zhejiang Hengkang Pharmaceutical Co., Ltd.
|
2023-04-04 | |||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-08-12 | ||
| $2.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY